DALLAS--Cytoclonal Pharmaceutics announced that it has launched a genome library of commercial reagents called Oasis that has the ability to regulate genes being uncovered by the Human Genome Project. Oasis, developed together with the University of Texas here, regulates genes using the company’s patented optimum antisense reagents. Cytoclonal’s other main platform is its Quantum Core Technology, a drug design technology that targets proteins involved in disease. "The combination of the Oasis genome library and the QCT drug design technology allows Cytoclonal to develop drugs based on gene and protein data," said Arthur Bollon, the company’s chairman and CEO. Cytoclonal plans to develop new compounds internally and license some of them to other companies.